The Indianapolis-based drugmaker reported a profit of $1.3 billion in the quarter ended Sept. 30, up 38 percent compared with last year. Excluding extraordinary items from a year ago, Lilly’s profit was up 2 percent.
Eli Lilly and Co. and its development partner said an experimental diabetes treatment failed to help patients in a late-stage study, the second setback for a Lilly diabetes drug candidate in two days.
Health care shows signs of life, and multi-family buildings continue to hold their own, experts said during a recent IBJ Power Breakfast.
Financial giant Principal Financial Group Inc. is exiting the health insurance business, a move that will cost 60 Indianapolis workers their jobs.
Amy Zucker is president of Indianapolis-based Synergy Marketing Group. Her firm was recently hired by Indianapolis-based ImmuneWorks Inc. to use a new website and search engine optimization to help recruit patients for a Phase 1 trial of ImmuneWorks experimental medicine idiopathic pulmonary fibrosis. The Web strategy is a new wrinkle on patient recruitment—in addition to the traditional partnerships with disease specialists at academic medical centers—that Zucker hopes leads to lower costs and faster clinical trials. Phase 1 clinical trials cost nearly $16,000 per patient.
Eli Lilly and Co. paid more than $102 million last year and early this year to physicians for talking up Lilly drugs to other doctors. Yet 88 of the doctors Lilly pays have been sanctioned by state medical boards.
Morgan Hospital & Medical Center is on the brink of merging with Clarian Health for a variety of reasons, but one of the biggest is one that all hospitals are facing in one way or another: a declining payer mix.
Columbus Regional Hospital officials say a decline in its number of inpatients and an increase in outpatients have them considering whether to proceed with a planned $108 million expansion project.
Indianapolis-based Eli Lilly and Co. will close its drug discovery center in Singapore, three years into a five-year, $150 million plan to expand it.
The company, which develops mass spectrometry devices used in the life sciences and industrial chemistry, has a new CEO, among other changes.
The city is kicking in up to $38 million for infrastructure upgrades to support a massive expansion of the Clarian Health campus at 16th Street and Capitol Avenue.
Until all consumers are required to buy health insurance, coverage restrictions are needed to keep people from gaming the system, insurers say.
Dr. Alexander B. Niculescu, a psychiatrist at the IU School of Medicine, has won a five-year, $1.5 million grant from the National Institutes of Health to hunt for the presence of certain proteins in the blood that would indicate that a patient suffers from a mood disorder, which afflicts one in five Americans.
Eli Lilly and Co.’s “miss” on a new use for its cancer drug Alimta was a rare failure to get an existing drug approved for a new use—even though the company has struggled mightily to get entirely new drugs to market.
Indianapolis-based WellPoint Inc. and competing U.S. health insurers approved $10 billion in stock repurchases in the past year, a concern to investors who say buybacks failed to increase share prices and who want more spent on dividends.
The developer of an unfinished medical office complex on Binford Boulevard has filed for Chapter 11 bankruptcy protection in hopes it can retain control of the property and resume construction later this year.
California-based life sciences firm Beckman Coulter Inc. is planning its third local expansion since 2007, investing $18.2 million in its Indianapolis operation and adding as many as 95 jobs here in the next three years.
The Indianapolis-based life insurer's investment portfolio held up through the recession, and the company reported record revenue and profit in 2009.
To date, most analysts say health reform turned out pretty well for the pharmaceutical industry. But a detailed analysis by Deloitte Consulting says the indirect effects of reform will deliver a gut punch to the industry that will lead to full-scale transformation akin to what the telecommunications world has seen over the past three decades.
